Instil Bio, Inc.
Index- P/E- EPS (ttm)-1.46 Insider Own2.45% Shs Outstand129.12M Perf Week1.70%
Market Cap639.85M Forward P/E- EPS next Y-1.91 Insider Trans0.00% Shs Float126.13M Perf Month-39.72%
Income-187.80M PEG- EPS next Q-0.41 Inst Own91.80% Short Float7.03% Perf Quarter-56.66%
Sales- P/S- EPS this Y-393.20% Inst Trans1.61% Short Ratio14.23 Perf Half Y-70.69%
Book/sh3.94 P/B1.21 EPS next Y-21.20% ROA-30.10% Target Price24.75 Perf Year-75.09%
Cash/sh2.84 P/C1.69 EPS next 5Y- ROE-32.60% 52W Range3.90 - 23.68 Perf YTD-72.06%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-79.81% Beta-
Dividend %- Quick Ratio10.60 Sales past 5Y- Gross Margin- 52W Low22.56% ATR0.62
Employees412 Current Ratio10.60 Sales Q/Q- Oper. Margin- RSI (14)37.61 Volatility9.96% 13.71%
OptionableYes Debt/Eq0.00 EPS Q/Q-133.30% Profit Margin- Rel Volume1.11 Prev Close4.83
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume622.84K Price4.78
Recom1.70 SMA20-11.22% SMA50-28.42% SMA200-64.43% Volume688,083 Change-1.04%
Aug-13-21Initiated Robert W. Baird Outperform $34
Apr-13-21Initiated Truist Buy $32
Apr-13-21Initiated Morgan Stanley Equal-Weight $24
Apr-13-21Initiated Cowen Outperform
May-27-22 07:00AM  
May-18-22 07:00AM  
May-16-22 07:00AM  
Mar-07-22 07:00AM  
Mar-02-22 07:00AM  
Nov-15-21 07:00AM  
Nov-10-21 11:28AM  
Nov-08-21 08:05AM  
Sep-16-21 07:00AM  
Sep-15-21 04:27PM  
Sep-13-21 07:00AM  
Sep-02-21 07:00AM  
Aug-12-21 07:00AM  
Jul-19-21 02:34PM  
Jun-21-21 10:06AM  
Jun-01-21 07:00AM  
May-13-21 07:00AM  
Apr-29-21 08:45AM  
Apr-27-21 07:00AM  
Apr-12-21 07:18AM  
Mar-23-21 05:00PM  
Mar-19-21 04:25PM  
Mar-18-21 08:26PM  
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.